ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

FDA To Regulate Products From Human Cells, Tissue

March 21, 1997

House Subcommittee Rejects Doubling Budget For Cancer Research, Provides Increase To NIH

July 17, 2009

CCI Gets Qualified Approval To Continue

January 18, 1980

In Brief: Innovative Antismoking Efforts Needed, CCRAC Told, Illinois To Go After Neutron Contract

December 8, 1978

DeVita: It Was Time To Go, and The Action Is Hot At Memorial: Says He’ll Work Well With Paul Marks

August 19, 1988

ODACSupports Temodal For Treatment of Astrocytoma

January 22, 1999